×
News Home

Do Traders Think Chromadex Corp (CDXC) Can Turn Around Wednesday?

Wednesday, September 28, 2022 11:32 AM | InvestorsObserver Analysts
Do Traders Think Chromadex Corp (CDXC) Can Turn Around Wednesday?

The market has been neutral on Chromadex Corp (CDXC) stock recently. CDXC gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,neutral
Chromadex Corp has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on CDXC!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CDXC Stock Today?

Chromadex Corp (CDXC) stock is trading at $1.34 as of 11:14 AM on Wednesday, Sep 28, an increase of $0.13, or 10.74% from the previous closing price of $1.21. The stock has traded between $1.22 and $1.36 so far today. Volume today is low. So far 49,765 shares have traded compared to average volume of 191,245 shares. To see InvestorsObserver's Sentiment Score for Chromadex Corp click here.

More About Chromadex Corp

ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. It delivers Niagen as the sole active ingredient in its consumer product namely, Tru Niagen which is available on Tru Niagen's website and through partnerships with retailers and distributors. Click Here to get the full Stock Report for Chromadex Corp stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App